http://investorshub.advfn.com/boards...ge_id=92252943


L-Dopa-Induced Dyskinesia

On May 22, 2013, the Company (AMBS) entered into a letter of intent to in-license a Phase II drug candidate in L-Dopa-Induced Dyskinesia Parkinson's Disease from an undisclosed 3rd party. Once licensed, the Company intends to initiate a Phase IIb clinical trial within 12 months...

http://biz.yahoo.com/e/130613/ambs8-k.html

Earlier in June we wrote an article for Seeking-Alpha discussing Parkinson's Disease and the problems that exist for patients as the disease progresses, including psychosis and the development of L-Dopa-induced dyskinesia (LID).

http://scr.zacks.com/files/June%2019...001_n50g1c.pdf

One of the companies we highlighted in the article was Addex Therapeutics and their Phase IIb ready drug candidate, dipraglurant for LID. We encourage investors to view that article for a background on the PD-LID market opportunity.

In brief, LID is a major side effect of L-Dopa use. LID is characterized by hyperkinetic movements, including chorea (abnormal involuntary movement), dystonia (sustained muscle contraction, abnormal posture), and athetosis (involuntary convoluted movements). It is most common at times of peak L-DOPA plasma concentrations (peakdose dyskinesia), although it may also occur when plasma concentrations rise and fall (diphasic dyskinesia) or uring off-time (off-period dystonia). There are no approved treatment options for LID. Approximately 50% of PD patients will experience LID after 4 to 6 years on Levodopa therapy. The number rises to 90% after 10 to 15 years.

It is a significant problem for patients and physicians seeking treatment for PD. In fact, a survey of key opinion leaders (KOLs) in the Parkinson's treatment space showed that dyskinesia is the most important unmet medical need in the treatment of PD after a disease modifying agent (Datamonitor 2011).

A quick search of the BioMed-Tracker and ClinicalTrials.gov websites shows several candidates beyond Phase I development for LID:....

G